Tag: Myron Cohen

HIV virus eradication is a complex health challenge due to its long-lived persistence and how it hides in latently infected cells that escape the body’s immune system. Effective HIV treatments have decreased the likelihood of someone developing AIDS, while helping individuals live long and healthy lives without transmission to sexual...

Almost 40 years after the discovery of HIV, a new NOVA program “Ending HIV in America” reflects on the history of one of the most elusive and deadly viruses to ever infect humans. Dr. Myron “Mike” Cohen, director of the UNC Institute for Global Health & Infectious Diseases is the...

The First Annual Global Health Scholars Symposium took place November 11, sponsored by the Institute of Global Health & Infectious Diseases (IGHID) and the Gillings School of Global Public Health (GSGPH). The symposium showcased over 30 investigators from UNC and global sites around the world, featuring MD/PhD students, doctoral candidates, postdoctoral...

This study led by the UNC Institute for Global Health & Infectious Diseases, will enroll 7,500 COVID-positive individuals to answer some of the biggest questions about COVID-19. Investigators explain the study in this video. Over two years into the COVID-19 pandemic and researchers still are looking to answer some of...

A big thanks to everyone who contributed to the success of IGHIDFest! during UNC Research Week. This was the first year that the Institute for Global Health & Infectious Diseases (IGHID) participated in the week long celebration of Carolina’s research and education enterprise. Our follow-up survey confirms what a recent study...

(Note: This post has been updated to reflect a schedule change.) Almost 40 years after the discovery of HIV, a new NOVA program “Ending HIV in America” reflects on the history of one of the most elusive and deadly viruses to ever infect humans. Myron “Mike” Cohen, MD, director of...

Researchers from the HIV Prevention Trials Network (HPTN) presented updated results from the HPTN 084 long-acting cabotegravir (CAB) for pre-exposure prophylaxis (PrEP) study at the AIDS 2022 conference in Montreal. New findings show reductions in HIV incidence were sustained in the 12 months following trial unblinding (November 5, 2020, through...

The 2022 HPTN Annual Meeting took place June 5-8 in Washington, D.C., bringing hundreds of worldwide researchers, collaborators, community representatives, and government health officials together to share updates and accomplishments and re-engage with each other as a community. HPTN Principal Investigators Myron Cohen, MD, director of the UNC Institute for...

In 2021, women and girls in sub-Saharan Africa accounted for three of five new HIV infections, and young women aged 15–24 years were three times as likely as young men in the same age group to be infected with HIV. Despite expanded access to oral PrEP, women are disproportionately affected...

UNC’s Institute of Global Health and Infectious Diseases Director Myron Cohen, MD, is the lead investigator of a study recently published in the Journal of the American Medical Association (JAMA) that shows bamlanivimab monotherapy reduced the incidence of infection in skilled nursing homes and assisted living facilities with high risk of SARS-CoV-2 exposure. The...

  Eli Lilly today released results of a clinical trial that found bamlanivimab, a monoclonal antibody, significantly reduced the risk of contracting COVID-19 among residents and staff of long-term care facilities. The Phase 3 trial was conducted in partnership with the NIH’s National Institute of Allergy and Infectious Diseases and...

Presented by Larry Corey, MD Past President and Director, Professor of Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center Professor, Medicine and Laboratory Medicine, University of Washington Corey is an internationally renowned expert in virology, immunology and vaccine development. His research focuses on herpes viruses, HIV, the novel...